September 2021 Volume 7 Issue 11

September 2021

Volume 7, Issue 11

This issue discusses fertility preservation for young patients with cancer, reviews treatment options for primary immune thrombocytopenia, and more.

Table of Contents

September 2021 Issue

You Make the Call

Reader Responses: Is JAK2 positivity clinically significant in this 28-year-old patient with Budd-Chiari syndrome?

Wednesday, September 1st, 2021
Here’s how readers responded to a You Make the Call question about the clinical significance of JAK2 positivity in a patient with Budd-Chiari syndrome. Disclaimer:...

Editor’s Corner: Chance Encounters of the Third Kind

Wednesday, September 1st, 2021
Many of us can think back to our days as greenhorn hematologists, walking into the vast poster hall at an American Society of Hematology...

The New ACCME Standards: A Pendulum Swung Too Far?

Wednesday, September 1st, 2021
In this edition, Judith Kleinerman, MD, talks about the implications of the Accreditation Council for Continuing Medical Education’s (ACCME’s) new Standards for Integrity and...

September 2021 Issue

ASH Directions

ASH Announces New ASH-AMFDP Hematology Scholars, First 10 Sites Join ASH Research Collaborative SCD...

Wednesday, September 1st, 2021
ASH Publishes Adapted Clinical Practice Guidelines for Management of VTE in Latin America The American Society of Hematology (ASH), in partnership with 12 Latin American...

Daratumumab and Hyaluronidase-fihj Combination Approved for Relapsed/Refractory MM

Wednesday, September 1st, 2021
The FDA has approved daratumumab and hyaluronidase-fihj, in combination with pomalidomide and dexamethasone (Pd), for the treatment of patients with relapsed or refractory MM....
The Society Pages

Remembering Alvin Zipursky, Paul Frenette, and more

Wednesday, September 1st, 2021
Remembering Alvin Zipursky (1930 – 2021) Alvin Zipursky, MD, a leader in the field of pediatric hematology, died on August 10.Dr. Zipursky was professor emeritus...

FDA Supports Inclusion of Pregnant and Breastfeeding Women in Clinical Trials

Wednesday, September 1st, 2021
Officials at the FDA have announced their commitment to work with other regulators and industry to support the inclusion of pregnant and lactating women...

Circulating Tumor DNA After Axi-Cel Stratifies Risk, Predicts Outcomes in LBCL

Wednesday, September 1st, 2021
While many patients with relapsed/refractory large B-cell lymphoma (LBCL) respond to treatment with axicabtagene ciloleucel (axi-cel), only a small subset of these responders experience...
WIB_icon

Flow Cytometry as a Prognostic Tool for Children With Down Syndrome and AML

Wednesday, September 1st, 2021
The use of flow cytometry alone to determine measurable residual disease (MRD) status did not sufficiently identify children with acute myeloid leukemia (AML) and...
WIB_icon

Blunted Response to COVID-19 Vaccines in Transplant and Cellular Therapy Recipients

Wednesday, September 1st, 2021
Many patients who undergo bone marrow transplant and CAR-T cell therapy do not mount a detectable humoral response to authorized COVID-19 vaccines, according to...

Daratumumab Plus CyBorD Improves Outcomes in Newly Diagnosed Light-Chain Amyloidosis

Wednesday, September 1st, 2021
Combining daratumumab with bortezomib, cyclophosphamide, and dexamethasone (CyBorD) resulted in higher rates of hematologic response as well as improved survival free from hematologic progression...

rFIXFc as Prophylaxis and Treatment in Pediatric Hemophilia B

Wednesday, September 1st, 2021
Results from the phase III B-LONG study published in Blood Advances found that recombinant factor IX Fc fusion protein (rFIXFc) was an effective prophylactic...

Second-Line Pembrolizumab Plus GVD in Relapsed/Refractory Classical Hodgkin Lymphoma

Wednesday, September 1st, 2021
Second-line pembrolizuab plus intravenous (IV) gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) led to high complete response (CR) rates in patients with relapsed/refractory classical Hodgkin...

Treatment Delays and Hemostatic Abnormalities Predict Death in Newly Diagnosed APL

Wednesday, September 1st, 2021
Major factors associated with early deaths in hospitalized patients with newly diagnosed acute promyelocytic leukemia (APL) included treatment delays and the incidence of hemostatic...

Reduced-Intensity Conditioning Transplant Superior to Continuous 5-Azacitidine in Older Patients With MDS

Wednesday, September 1st, 2021
In older patients with advanced myelodysplastic syndromes (MDS), reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) improved event-free survival (EFS) compared with continuous 5-azacitidine therapy....

Conserving Red Blood Cell Units in the Treatment of Patients With SCD During Blood...

Wednesday, September 1st, 2021
The ongoing COVID-19 pandemic has led to severe blood shortages within the health care delivery system, disproportionately affecting the supply of red blood cells...

Oblimersen Shows No Added Benefit in Newly Diagnosed Acute Myeloid Leukemia

Wednesday, September 1st, 2021
The addition of BCL-2 antisense oligonucleotide oblimersen to standard induction chemotherapy did not improve remission rates in older patients with newly diagnosed acute myeloid...

Polatuzumab as Bridging or Salvage Therapy for Patients With Relapsed/Refractory LBCL

Wednesday, September 1st, 2021
Polatuzumab vedotin was approved in 2019 in combination with bendamustine and rituximab for patients with relapsed or refractory large B-cell lymphoma (LBCL). It showed...
WIB_icon

Belumosudil Induces Responses in Refractory Chronic Graft-Versus-Host Disease

Wednesday, September 1st, 2021
Belumosudil, a selective Rho-associated coiled-coil–containing protein kinase-2 (ROCK2) inhibitor, was associated with organ responses in heavily pretreated patients with chronic graft-versus-host disease (cGVHD) that...

Cancer Death Rates Fell 1.4% More in Early Medicaid Expansion States

Wednesday, September 1st, 2021
According to a new study published in the Journal of the National Cancer Institute, cancer death rates declined more sharply in U.S. states that...

FDA Committee Votes Against Approval of Roxadustat for Anemia of Chronic Kidney Disease

Wednesday, September 1st, 2021
The FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has decided not to recommend the approval of roxadustat for the treatment of patients with...
WIB_icon

Danicopan Improves Hemoglobin, Reduces Transfusion Requirements in Eculizumab-Treated Patients With PNH

Wednesday, September 1st, 2021
First-in-class oral factor D inhibitor danicopan improved hemoglobin (Hb) and reduced transfusion requirements in transfusion-dependent patients with paroxysmal nocturnal hemoglobinuria (PNH) who had previously...

ALLO-605 Receives FDA Fast Track Designation for Relapsed/Refractory MM

Wednesday, September 1st, 2021
The U.S. Food and Drug Administration (FDA) has granted fast track designation to ALLO-605 for the treatment of adult patients with relapsed or refractory...

Daratumumab and Hyaluronidase-fihj Combination Approved for Relapsed/Refractory MM

Wednesday, September 1st, 2021
The FDA has approved daratumumab and hyaluronidase-fihj, in combination with pomalidomide and dexamethasone (Pd), for the treatment of patients with relapsed or refractory MM....

September 2021 Issue

Pulling Back the Curtain: Glaivy Batsuli, MD

Wednesday, September 1st, 2021
In this edition, Glaivy Batsuli, MD, talks about coming to research “late” and the mentor who taught her to think like a scientist.   Where did...

The Preservation Conversation

Wednesday, September 1st, 2021
Discussions about possible infertility in young patients with cancer should happen early, and often. Chemotherapy, radiation, and hematopoietic cell transplantation (HCT) are essential treatment options...

September 2021 Issue

You Make the Call

You Make the Call: Is JAK2 positivity clinically significant in this 28-year-old patient with Budd-Chiari...

Wednesday, September 1st, 2021
This month, Peter Emanuel, MD, discusses the clinical significance of JAK2 positivity in a patient with Budd-Chiari syndrome. And don't forget to check out next...
How I Treat In Brief

Corticosteroid-Dependent or Corticosteroid-Unresponsive Primary ITP

Wednesday, September 1st, 2021
This month, Waleed Ghanima, MD, PhD, Terry Gernsheimer, MD, and David J. Kuter, MD, DPhil, review treatment options for adult patients with primary immune...